4McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide compared with paclitaxel and cisplatin in patients with stage Ⅲ and Ⅳ ovarian cancer. N Engl J Med, 1996, 334: 1-6.
5Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Nat Cancer Inst, 2000,92 : 699-708.
6The ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2. 2triaL Lancet, 2003,361:2099-2106.
7Fennelly D, Aghajanian C, Shapiro F, et aL Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol, 1997,15: 187-192.
8Markman M, Hall J, Spitz D, et aL Phase H trial of weekly singleagent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol, 2002,20:2365-2369.
9Ozols RF, Bundy BN, Greer BE, et aL Phase Ⅲ trial of carboplatin and paclitaxel compared with cisphtin and paclitaxel in patients with optimally resected stage Ⅲ ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol, 2003,21 : 3194-3200.
10Bois A du, Luck HI, Meier W. et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Nail Cancer Inst, 2003,95: 1320-1330.
